DSpace Repository

Efficacy of Dehydroepiandrosterone (DHEA) to overcome the effect of ovarian ageing (DITTO): A proof of principle double blinded randomized placebo controlled trial

Show simple item record

dc.contributor.author Narkwichean A.
dc.contributor.author Maalouf W.
dc.contributor.author Baumgarten M.
dc.contributor.author Polanski L.
dc.contributor.author Raine-Fenning N.
dc.contributor.author Campbell B.
dc.contributor.author Jayaprakasan K.
dc.date.accessioned 2021-04-05T03:21:59Z
dc.date.available 2021-04-05T03:21:59Z
dc.date.issued 2017
dc.identifier.issn 3012115
dc.identifier.other 2-s2.0-85029532377
dc.identifier.uri https://ir.swu.ac.th/jspui/handle/123456789/13001
dc.identifier.uri https://www.scopus.com/inward/record.uri?eid=2-s2.0-85029532377&doi=10.1016%2fj.ejogrb.2017.09.006&partnerID=40&md5=9356158b78b61815f6d573dc4e140642
dc.description.abstract Objective To evaluate the effect of DHEA supplementation on In-Vitro Fertilisation (IVF) outcome as assessed by ovarian response, oocyte developmental competence and live birth rates in women predicted to have poor ovarian reserve (OR). The feasibility of conducting a large trial is also assessed by evaluating the recruitment rates and compliance of the recruited participants with DHEA/placebo intake and follow-up rates. Study design A single centre, double blinded, placebo controlled, randomized trial was performed over two years with 60 women undergoing in-vitro fertilisation (IVF). Subjects were randomized, based on a computer-generated pseudo-random code to receive either DHEA or placebo with both capsules having similar colour, size and appearance. 60 women with poor OR based on antral follicle count or anti-Mullerian hormone thresholds undergoing IVF were recruited. They were randomised to receive DHEA 75 mg/day or placebo for at-least 12 weeks before starting ovarian stimulation. They had long protocol using hMG 300 IU/day. Data analysed by “intention to treat”. Ovarian response, live birth rates and molecular markers of oocyte quality were compared between the study and control groups. Results The recruitment rate was 39% (60/154). A total of 52 participants (27 versus 25 in the study and placebo groups) were included in the final analysis after excluding eight. While the mean (standard deviation) DHEA levels were similar at recruitment (9.4 (5) versus 7.5 (2.4) ng/ml; P = 0.1), the DHEA levels at pre-stimulation were higher in the study group than in the controls (16.3 (5.8) versus 11.1 (4.5) ng/ml; P < 0.01). The number (median, range) of oocytes retrieved (4, 0–18 versus 4, 0–15 respectively; P = 0.54) and live birth rates (7/27, 26% versus 8/25, 32% respectively; RR (95% CI): 0.74 (0.22-2.48) and mRNA expression of developmental biomarkers in granulosa and cumulus cells were similar between the groups. Conclusion Pre-treatment DHEA supplementation, albeit statistical power in this study is low, did not improve the response to controlled ovarian hyperstimulation or oocyte quality or live birth rates during IVF treatment with long protocol in women predicted to have poor OR. © 2017
dc.subject ampiregulin
dc.subject betaregulin
dc.subject biological marker
dc.subject buserelin
dc.subject chorionic gonadotropin
dc.subject cyclooxygenase 2
dc.subject epiregulin
dc.subject follitropin receptor
dc.subject GREM1 protein
dc.subject human menopausal gonadotropin
dc.subject hyaluronan synthase 2
dc.subject luteinizing hormone receptor
dc.subject messenger RNA
dc.subject molecular marker
dc.subject Muellerian inhibiting factor
dc.subject nafarelin
dc.subject nafarelin acetate
dc.subject pentraxin 3
dc.subject placebo
dc.subject prasterone
dc.subject progesterone
dc.subject PTGS2 protein
dc.subject somatomedin C
dc.subject unclassified drug
dc.subject androgen
dc.subject prasterone
dc.subject acne
dc.subject adult
dc.subject antral follicle count
dc.subject Article
dc.subject birth rate
dc.subject clinical outcome
dc.subject controlled study
dc.subject cumulus cell
dc.subject double blind procedure
dc.subject drug efficacy
dc.subject drug withdrawal
dc.subject embryo
dc.subject embryo transfer
dc.subject female
dc.subject follow up
dc.subject gastrointestinal symptom
dc.subject gene expression profiling
dc.subject granulosa cell
dc.subject human
dc.subject in vitro fertilization
dc.subject intention to treat analysis
dc.subject intracytoplasmic sperm injection
dc.subject live birth
dc.subject major clinical study
dc.subject nausea
dc.subject oily skin
dc.subject oocyte development
dc.subject oocyte retrieval
dc.subject ovarian reserve
dc.subject ovary hyperstimulation
dc.subject pregnancy outcome
dc.subject priority journal
dc.subject randomized controlled trial
dc.subject single embryo transfer
dc.subject aging
dc.subject drug effect
dc.subject metabolism
dc.subject oocyte
dc.subject ovary
dc.subject ovulation induction
dc.subject pregnancy
dc.subject procedures
dc.subject Adult
dc.subject Aging
dc.subject Androgens
dc.subject Dehydroepiandrosterone
dc.subject Double-Blind Method
dc.subject Female
dc.subject Fertilization in Vitro
dc.subject Humans
dc.subject Intention to Treat Analysis
dc.subject Live Birth
dc.subject Oocyte Retrieval
dc.subject Oocytes
dc.subject Ovarian Reserve
dc.subject Ovary
dc.subject Ovulation Induction
dc.subject Pregnancy
dc.title Efficacy of Dehydroepiandrosterone (DHEA) to overcome the effect of ovarian ageing (DITTO): A proof of principle double blinded randomized placebo controlled trial
dc.type Article
dc.rights.holder Scopus
dc.identifier.bibliograpycitation European Journal of Obstetrics and Gynecology and Reproductive Biology. Vol 218, (2017), p.39-48
dc.identifier.doi 10.1016/j.ejogrb.2017.09.006


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics